NP 001

Drug Profile

NP 001

Alternative Names: NP001

Latest Information Update: 30 Aug 2016

Price : $50

At a glance

  • Originator Neuraltus Pharmaceuticals
  • Class Neuropsychotherapeutics; Small molecules
  • Mechanism of Action Immunomodulators; Macrophage modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Amyotrophic lateral sclerosis
  • Preclinical Alzheimer's disease; Ataxia telangiectasia; Dementia; Parkinson's disease

Most Recent Events

  • 22 Sep 2016 Neuraltus Pharmaceuticals initiates a phase II trial for Amyotrophic lateral sclerosis in USA (9203725; NCT02794857)
  • 23 Jun 2016 Neuraltus Pharmaceuticals plans a phase II trial for Amyotrophic lateral sclerosis in USA (NCT02794857)
  • 04 Apr 2016 Interim pharmacodynamics data from a secondary analyses of phase II trial in Amyotrophic lateral sclerosis released by Neuraltus
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top